The Lupus Research Alliance, the world’s largest private funder of lupus research, and Pfizer Inc., the global biopharmaceutical company, announced the start of a non-interventional clinical study that will test a custom smartphone app enabling lupus patients to report on their fatigue and other symptoms in real time. Incorporating feedback from people with lupus, the new app will be evaluated through a non-interventional clinical study called VALUE (VAlidation in LUpus of an Electronic Patient Reported Outcomes Tool), scheduled to begin at the end of this month.
You are here
Press Release Archive
Pfizer Inc., the Bill & Melinda Gates Foundation, and the Children’s Investment Fund Foundation (CIFF) today announced a multi-year extension of their collaboration to further broaden access to Pfizer’s all-in-one injectable contraceptive, Sayana® Press (medroxyprogesterone acetate), for women most in need in some of the world’s poorest countries. Sayana Press will now be available to qualified purchasers at a guaranteed price of US $0.85 per dose, a reduction from the previous price of US $1.00 per dose.
Pfizer Inc. (NYSE:PFE) announced today that detailed results from the Phase 3 Oral Clinical Trials for tofAcitinib in ulceratiVE colitis (OCTAVE) clinical program were published in The New England Journal of Medicine (NEJM).
Pfizer Inc. announced today...
The board of directors of Pfizer Inc. today declared a 32-cent second-quarter 2017 dividend on the company’s common stock, payable June 1, 2017, to shareholders of record at the close of business on May 12, 2017. The second-quarter 2017 cash dividend will be the 314th consecutive quarterly dividend paid by Pfizer.
Pfizer Inc. today announced that its investigational next-generation ALK/ROS1 tyrosine kinase inhibitor, lorlatinib, was granted Breakthrough Therapy designation from the U.S. Food and Drug Administration (FDA) for the treatment of patients with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC), previously treated with one or more ALK inhibitors.
Positive results of the...
Pfizer Inc. today announced the launch of the company’s Antimicrobial Testing Leadership and Surveillance (ATLAS) website, which is designed to provide physicians and the global health community with easy access to critical data on the efficacy of various antibiotic treatments and emerging resistance patterns across more than 60 countries.
The international nonprofit organization Population Services International (PSI) and the biopharmaceutical company Pfizer Inc. (NYSE:PFE) today announced Healthy Communities, a US $1 million collaboration to expand access to life-saving hypertension medicines and treatment services in Myanmar and Vietnam.
Pfizer Inc. (NYSE:PFE) today announced that the U.S. Food and Drug Administration (FDA) has approved a supplemental New Drug Application (sNDA) for its first-in-class cyclin dependent kinase 4/6 (CDK 4/6) inhibitor, IBRANCE® (palbociclib), based on the results from the confirmatory Phase 3 trial PALOMA-2. The FDA action converts the accelerated approval of IBRANCE to regular approval and broadens the range of anti-hormonal therapy that may be administered with IBRANCE.
TRUMENBA Has Been Studied in a Global Clinical Development Program Evaluating the Vaccine in Adolescents and Adults
EMD Serono, the biopharmaceutical business of Merck KGaA, Darmstadt, Germany in the US and Canada, and Pfizer Inc. (NYSE: PFE) today announced that the US Food and Drug Administration (FDA) has approved BAVENCIO® (avelumab) Injection 20 mg/mL, for intravenous use, for the treatment of adults and pediatric patients 12 years and older with metastatic Merkel cell carcinoma (mMCC). This indication is approved under accelerated approval based on tumor response and duration of response.
Pfizer China announced today that it has received approval from the Chinese Food and Drug Administration (CFDA) to market its oral Janus kinase (JAK) inhibitor, XELJANZ
Servier, together with Pfizer Inc. (NYSE:PFE) and Cellectis (Paris:ALCLS) (NASDAQ:CLLS) (Alternext: ALCLS; Nasdaq: CLLS), announced today that the U.S. Food and Drug Administration (FDA) has granted Servier with an Investigational New Drug (IND) clearance to proceed in the U.S. with the clinical development of UCART19, an allogeneic, gene-edited cellular therapy candidate to treat relapsed/refractory acute lymphoblastic leukemia.
Pfizer Inc. invites investors and the general public to listen to a webcast of a discussion with Frank D’Amelio, Executive Vice President, Business Operations and Chief Financial Officer, at the Barclays Global Healthcare Conference on Wednesday, March 15, 2017 at 1:35 p.m. Eastern Daylight Time.
Note: These press releases were issued in the United States and are intended as reference information for U.S. investors and journalists. The information contained in each press release was accurate at the time of issuance, and Pfizer assumes no responsibility for updating the information to reflect subsequent developments.
Stock Quote Disclaimer
20 minute delayed data provided by Comstock. Charts are provided by BigCharts and MarketWatch, Inc. Pfizer makes no claims concerning the accuracy of the information provided on these pages, and will not be held liable for any use of this information. Note: Historical and current stock price performance data is not necessarily indicative of future performance.
If you do not have Adobe® Reader, download it here. It is available without charge from Adobe®. This link is provided as a convenience. Pfizer is not responsible for the content of this linked page.